A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316)

Author:

Javid Sara H.1,Unger Joseph M.2,Gralow Julie R.3,Moinpour Carol M.2,Wozniak Antoinette J.4,Goodwin J. Wendall5,Lara Primo N.6,Williams Pamela A.7,Hutchins Laura F.8,Gotay Carolyn C.9,Albain Kathy S.10

Affiliation:

1. a Department of Surgery, Division of Surgical Oncology, University of Washington, Seattle, Washington, USA;

2. c SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA;

3. b Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA;

4. d Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA;

5. e Ozarks Regional Community Clinical Oncology Program, Springfield, Missouri, USA;

6. f Department of Medicine, Division of Hematology/Oncology, University of California at Davis, Sacramento, California, USA;

7. g Department of Oncology Research, Upstate Carolina Community Clinical Oncology Program, Spartanburg, South Carolina, USA;

8. h Department of Medicine, Division of Hematology/Oncology, University of Arkansas, Little Rock, Arkansas, USA;

9. i School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada;

10. j Department of Medicine, Division of Hematology/Oncology, Stritch School of Medicine, Loyola University, Chicago, Illinois, USA

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Cite reasons given by patients older than 65 years for their decisions to participate or not to participate in clinical trials.Cite reasons given by physicians for their decisions not to enroll patients older than 65 years in clinical trials or discuss enrollment with these patients. CME This article is available for continuing medical education credit at CME.TheOncologist.com Purpose. Patients older than 65 years are underrepresented in clinical trials. We conducted a prospective study (SWOG S0316) to determine physician- and patient-perceived barriers to breast cancer clinical trial enrollment for older patients. Methods. Eight geographically diverse SWOG institutions participated. The study assessed patients' and physicians' decisions to enroll in or decline clinical treatment trials, including demographics, trial availability, and eligibility. Patient and physician questionnaires elicited concerns related to treatment, medical status, age, family, and financial or transportation concerns. Results. A total of 1,079 patients were registered and eligible and 909 (84%) returned for follow-up. The major reason for nonaccrual was either trial unavailability or ineligibility (60%). Older patients were less likely to be eligible for trials (65% for age ≥65 years vs. 78% for age <65 years). If eligible, trial participation rates did not differ significantly by age (34% for age ≥65 years vs. 40% for age <65 years). Patients ≥65 years more often were concerned about side effects, had friends opposed to participation, or believed that participation would not benefit other generations. When trials were available and patients were eligible, physicians discussed trial participation with 76% of patients <65 years versus 58% of patients ≥65 years of age. For patients ≥65 years, 11% of physicians indicated age as a reason they did not enroll a patient in a clinical trial. Conclusion. Trial unavailability or patient ineligibility were the major reasons for lack of enrollment in breast cancer clinical trials for patients of all ages in this prospective study. Older patients were less likely to be eligible for trials, but if eligible they participated at similar rates to younger patients.

Funder

Breast Cancer Research Foundation

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference29 articles.

1. Underrepresentation of patients 65 years of age or older in cancer-treatment trials;Hutchins;N Eng J Med,1999

2. Aging and cancer in America. Demographic and epidemiologic perspectives;Yancik;Hematol Oncol Clin North Am,2000

3. Underrepresentation of women in clinical drug trials;Schmucker;Clin Pharmacol Ther,1993

4. Women, research, and the National Institutes of Health;Pinn;Am J Prev Med,1992

5. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs: Notice;Food and Drug Administration;Fed Regist,1993

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3